Parameter | CRT/CT only | n=33 | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
Progression free survival | Overall survival | |||||||||
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |||
Performance status | ECOG 0 | 23 | NR | NR | ||||||
ECOG 1 | 10 | 1.23 (0.55 to 2.77) | 0.61 | 1.03 (0.38 to 2.76) | ||||||
Systemic CT+CRT | No | 22 | NR | NR | ||||||
Adjuvant CT | 5 | 0.91 (0.29 to 2.81) | 0.867 | 0.88 (0.25 to 3.09) | 0.845 | |||||
Neoadjuvant CT | 6 | 0.66 (0.24 to 1.80) | 0.413 | 0.53 (0.12 to 2.35) | 0.406 | |||||
Symptoms at diagnosis | Other | 9 | NR | NR | ||||||
PCB/PMB | 24 | 0.48 (0.21 to 1.11) | 0.085 | 0.47 (0.18 to 1.23) | 0.126 | |||||
Histology | Adenocarcinoma | 8 | NR | NR | ||||||
Squamous cell carcinoma | 22 | 1.07 (0.42 to 2.73) | 0.883 | 1.60 (0.46 to 5.60) | 0.458 | |||||
Other | 3 | 2.08 (0.51 to 8.41) | 0.306 | 1.44 (0.24 to 8.74) | 0.695 | |||||
Grade | Moderately differentiated | 7 | NR | NR | ||||||
Well differentiated | 4 | 0.97 (022 to 4.32) | 0.963 | 0.83 (0.08 to 8.16) | 0.872 | |||||
Poorly differentiated | 22 | 2.0 (0.67 to 5.89) | 0.212 | 1.84 (0.53 to 6.46) | 0.338 | |||||
PD-L1 CPS status | Unknown | 19 | NR | NR | ||||||
<1% | 7 | 5.20 (1.85 to 14.60) | 0.00176 | 0.74 (0.20 to 2.64) | 0.638 | |||||
≥1% | 7 | 2.57 (0.98 to 6.76) | 0.05588 | 0.43 (0.15 to 1.26) | 0.124 | |||||
Para-aortic lymph nodes | No | 12 | NR | NR | ||||||
Yes | 21 | 1.29 (0.58 to 2.89) | 0.529 | 2.61 (0.92 to 7.38) | 0.071 | |||||
Pelvic lymph nodes | No | 3 | NR | NR | ||||||
Yes | 30 | 1.05 (0.30 to 3.60) | 0.944 | 2.88 (0.38 to 21.7) | 0.304 | |||||
Pattern of metastasis | Hematogenous spread | 19 | NR | NR | ||||||
Lymphatic spread | 14 | 0.45 (0.20 to 0.99) | 0.049 | 0.43 (0.19 to 1.0) | 0.0502 | 0.82 (0.33 to 2.06) | 0.673 | 0.65 (0.21 to 1.97) | 0.4437 | |
Oligometastatic vs polymetastatic | Oligometastatic disease | 25 | NR | NR | ||||||
Polymetastatic disease | 8 | 2.22 (0.95 to 5.18) | 0.065 | 1.12 (0.33 to 3.74) | 0.8598 | 1.09 (0.39 to 3.08) | 0.867 | 0.32 (0.06 to 1.74) | 0.1903 | |
Brachytherapy | Yes | 20 | NR | NR | ||||||
No | 13 | 0.40 (0.75 to 3.57) | 0.219 | 1.0 (0.39 to 2.56) | 0.995 | |||||
RT to all sites | No | 10 | NR | NR | ||||||
Yes | 23 | 0.38 (0.17 to 0.86) | 0.019 | 0.38 (0.12 to 1.17) | 0.0917 | 0.51 (0.20 to 1.31) | 0.162 | 0.25 (0.06 to 1.03) | 0.0544 | |
Time to completion of RT | ≤8 weeks | 9 | NR | NR | ||||||
>8 weeks | 14 | 0.81 (0.29 to 2.24) | 0.684 | 0.90 (0.24 to 3.31) | 0.868 | |||||
Best response after CRT | CR | 14 | NR | NR | ||||||
PR | 9 | 6.67 (2.23 to 19.9) | 0.0006 | 4.76 (1.12 to 20.2) | 0.034 | |||||
PD | 10 | 4.60 (1.64 to 12.9) | 0.003 | 14.1 (3.52 to 59.9) | 0.0001 |
CPS, combined pathology score; CR, complete response; CRT, chemoradiation; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; NR, not reached; PCB, post-coital bleeding; PD, progressive disease; PD-L1, programmed death ligand 1; PMB, post-menopausal bleeding; PR, partial response; RT, radiation therapy.